Boston Scientific’s BSX Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technologies. The ...

Boston Scientific's Q1 2025 Endoscopy sales jump 6%, ... AXIOS is the first and only stent indicated for transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts.

Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10% ...

Boston Scientific (NYSE:BSX) recently entered into a significant agreement with Bittium Biosignals Ltd. to supply ECG devices, valued between USD 30 to 45 million, which strengthens their cardiac ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will no longer pursue an approval in the U.S., following recent stu | It’s ...

Shares of Boston Scientific slipped 0.7% to $105.46 in early trading Wednesday, while shares of Edwards rose 1.8% to $77.60 and shares of Medtronic gained 1.1% to $82.06.

Boston Scientific (BSX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Boston Scientific and J.&J. Settle Suit Over Guidant Deal Boston Scientific agreed to pay Johnson & Johnson $600 million in connection with Johnson & Johnson’s botched acquisition of Guidant, a ...